Breaks Categories: News

FridayNov 06, 2020 9:16 am

BioMedNewsBreaks – Turning Point Therapeutics Inc. (NASDAQ: TPTX) Secures $460M in Underwritten Public Offering

Turning Point Therapeutics (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, has closed an underwritten public offering of 5,287,357 shares of its common stock, including 689,655 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Turning Point Therapeutics secured approximately $460 million in gross proceeds, with each of the shares sold at the public offering price of $87.00. Roth Capital Partners acted as co-manager for the offering. For more information, visit the company’s website at: www.TPTherapeutics.com About Turning Point Therapeutics Turning Point is a…

Continue Reading

ThursdayNov 05, 2020 12:30 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced the appointment of Dr. Khalid Islam to its board of directors. Dr. Islam was the chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led its transition to a profitable company that subsequently sold for US$1 billion. In addition, he is currently an advisor to the venture group Kurma Biofund (Paris), the chairman of the board for Fennec Pharmaceuticals Inc. (NASDAQ: FENC), Gain Therapeutics Inc. and Minoryx Therapeutics SL, and…

Continue Reading

ThursdayNov 05, 2020 11:55 am

BioMedNewsBreaks – Applied UV Inc. (NASDAQ: AUVI) Enters Non-Binding LOI to Acquire Airocide(TM) System for Airborne Pathogen Reduction

Applied UV (NASDAQ: AUVI), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens, today announced its entry into a non-binding letter of intent ("LOI") with Akida Holdings LLC. In addition to its exclusive joint distribution and licensing agreement with Akida Holdings, the LOI is to explore the possibility of acquiring certain key assets of Akida. This includes Akida’s rights to the manufacture and sale of the Airocide(TM) System of patented, air purification technologies, which may aid in the reopening of the global economy with applications in the…

Continue Reading

WednesdayNov 04, 2020 12:37 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Report Q3 2020 Financial Results, Host Conference Call

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced that it will release financial results for its second quarter ended September 30, 2020, on Thursday, Nov. 12, 2020, as well as host a conference call at 9:00 a.m. Eastern Time. According to the update, Erez Raphael, chief executive officer, Rick Anderson, president and general manager of North America and Zvi Ben-David, chief financial officer will host the call. Interested parties may register via the webcast link and join the call by dialing 844-369-8770 (Toll-Free) or 862-298-0840 (International) and providing the following conference ID: DarioHealth Third Quarter…

Continue Reading

TuesdayNov 03, 2020 2:58 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Stock2Me Podcast

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Shawn K. Singh, CEO of VistaGen, as he discusses the company’s innovative development pipeline and focus on bringing new, effective treatment options for anxiety, depression and other conditions involving the central nervous system (“CNS”) for which the company believes current treatment alternatives are inadequate, resulting in high unmet need. “Throughout the many years I’ve…

Continue Reading

TuesdayNov 03, 2020 1:02 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Call, Live Webcast to Discuss Q3 2020 Results, Clinical Pipeline

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, today announced that it will host a conference call and live webcast at 5:30 p.m. Eastern Time on Nov. 12, 2020. Topics will include review of the company’s third quarter 2020 results and an update on its clinical pipeline, including discussion of PCSA’s three clinical-stage drugs (each of which addresses potential billion-dollar markets). Interested parties may join the call by dialing 877-876-9176 (Toll Free) or 785-424-1670 (International) and access the live webcast via the following…

Continue Reading

TuesdayNov 03, 2020 12:00 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Appoints Experienced Innovator as VP of Strategy

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced the appointment of a new vice president of strategy and business development. In her new role, Amy Griffith will be responsible for the company’s development of strategic and tactical initiatives, as well as new sales strategies. A veteran sales and innovation expert, Griffith has held executive management positions at leading technology companies and has also worked with start-ups, focusing on identifying and implementing strategic sales programs. With an expertise in the medical and health-care industry, Griffith has been deeply involved and brings impressive experience in strategic planning and…

Continue Reading

MondayNov 02, 2020 12:10 pm

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Announces Q3 Growth of DetermaRx(TM) Physician Adoption, Testing Volume

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, recently provided an update on DetermaRx’s global growth and adoption. According to the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high risk of recurrence, despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. Since its January commercial launch in the U.S., DetermaRx has begun to be reimbursed by Medicare and multiple private payers and has seen rapid adoption across 67 hospitals. “We…

Continue Reading

MondayNov 02, 2020 11:49 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures $6.9M in Private Placement

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, earlier this year announced the closing of a private placement financing (the “offering”). According to the update, AzurRx secured approximately $6.9 million in gross proceeds from certain accredited investors, with Alexander Capital LP acting as sole placement agent in the offering. The company intends to use net proceeds to eliminate short- and long-term indebtedness, as well as for general working capital purposes including product development. “We are very grateful for the continued support of our investors,” James Sapirstein, president and CEO of AzurRx said…

Continue Reading

FridayOct 30, 2020 1:50 pm

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Named Among the 2020 Best Places to Work in Orange County

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, on Wednesday announced it has been named as one of the 2020 Best Places to Work in Orange County. Oncocyte ranked number four out of 40 in the medium-size company category. A project of the Orange County Business Journal and Best Companies Group, the awards program was created in 2009. “Great technologies and great strategies don’t do great things; great people accomplish great things,” said Ron Andrews, CEO of Oncocyte. “While our world of molecular diagnostics…

Continue Reading